Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact

on monday, Sangamo Therapeutics, Inc.. (NASDAQ:SGMO) has regained the development and commercialization rights to gyloctocogene fitelparvovec, an investigational gene therapy product candidate for moderate to severe hemophilia A that it co-developed and licensed with the company. Pfizer Inc. (NYSE:PFE).

Pfizer decides to end global collaboration and licensing agreements between the parties. Sangamo intends to explore all options to advance the program, including seeking potential new collaboration partners.

Also read: FDA approves Pfizer’s second hemophilia drug with six-month deadline

In July 2024, Pfizer announced topline results from the Phase 3 AFFINE trial of gyloctocogene fitelparvovec, demonstrating that the trial met its primary objective of superiority and important secondary objectives. did. compared to prevention.

Sangamo Therapeutics Chief Executive Officer Sandy McRae said, “…we believe we are well-positioned for potential regulatory filings and commercialization.” . “We were surprised and deeply disappointed by Pfizer’s decision to end our partnership with the anticipated BLA and MAA filings just around the corner.”

Our partnership and license agreement with Pfizer ends on April 21, 2025. All trial participants will continue to be monitored as planned during the transition period.

Sangamo recently announced the partnership: Roche Holdings AG (OTC:RHHBY) genentech and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) and advanced business development discussions regarding Fabry gene therapy programs will help chart the future path for the neurology genomic medicine pipeline.

The company plans to begin enrolling patients in a Phase 1/2 trial of ST-503 in idiopathic small fiber neuropathy in mid-2025, and plans to begin enrollment in its prion disease program in the fourth quarter of 2025. Preparations are underway to submit an application for clinical trial approval. securing additional funding;

Price action: SGMO stock fell 54.70% to $1.106 during the pre-market session at last check on Tuesday.

Read next:

Next step: Transform your trading with Benzinga Edge’s unique market trading ideas and tools. Click now to access unique insights That gives you an edge in today’s competitive market.

Want the latest stock analysis from Benzinga?

This article Sangamo Therapeutics stock plummets as Pfizer terminates hemophilia gene therapy agreement originally appeared Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. Unauthorized reproduction is prohibited.